Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).

Trial Profile

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs ALT 803 (Primary) ; Epacadostat (Primary) ; MSB 0011359C (Primary) ; MVA brachyury TRICOM vaccine (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms QuEST1
  • Most Recent Events

    • 19 Apr 2018 Planned initiation date changed from 17 Apr 2018 to 25 Apr 2018.
    • 18 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 13 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top